A 3-month course of romosozumab followed by denosumab produced bone density gains comparable to those of the standard 12-month regimen in postmenopausal women at high fracture risk.
Fresenius Kabi continues the expansion of its biosimilars portfolio in the U.S. with the introduction of Conexxence (denosumab-bnht) and Bomyntra® (denosumab-bnht) in the United States. Bomyntra is ...
Elucidation of the molecular pathways underlying bone turnover has revealed potential therapeutic targets, including receptor activator of nuclear factor-κB ligand (RANKL), which is a mediator of ...
Longer durations of denosumab treatment improved the probability of achieving target T-scores at the total hip and lumbar spine in postmenopausal women with osteoporosis. Denosumab treatment ...
Patients with bone metastases from solid tumors typically are treated with either zoledronic acid or denosumab to reduce the risk for future skeletal metastases. However, therapy for bone metastases ...
The receptor activator of nuclear factor kappa B ligand (RANKL) signaling pathway is a key mediator of bone remodeling and so represents an attractive target for the development of novel osteoporosis ...
— Sandoz Canada has a leading biosimilars portfolio, with many more in the pipeline BOUCHERVILLE, Quebec, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Sandoz Canada, a leader in generics and biosimilars, today ...
Denosumab significantly reduced fractures in postmenopausal women with breast cancer receiving aroma The medication inhibits bone resorption but is associated with prolonged elevation in PTH levels ...
Symptom burden in cancer survivors 1 year after diagnosis: A report from the American Cancer Society's studies of cancer survivors. Background: Bone metastases from solid tumors increase risk for ...
A new drug called denosumab may soon give Zometa (zoledronic acid) competition as the standard of care in treating bone metastases in patients with advanced breast cancer. Patients taking denosumab ...
The researchers found that with denosumab vs oral bisphosphonates, the risk for emergently treated hypocalcemia increased with worsening CKD stage. (HealthDay News) — For patients with chronic kidney ...
For dialysis-dependent patients treated for osteoporosis, denosumab is associated with a greater preventive effect on fractures but an increased risk for major adverse cardiovascular events (MACE) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results